Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PGPratyush GiriTCTara CochraneMWMannu Walia

Discussion

Loading...

Member takes

Overview

Interim analysis reveals Pembro plus R-CHOP improves event free survival in PMBL, highlighting low rates of adverse events.

Key Points

  • To evaluate the efficacy and safety of Pembrolizumab combined with R-CHOP as first-line therapy for PMBL.
  • Phase II, single arm, open-label study
  • Patients received 2 cycles of rituximab plus Pembrolizumab followed by R-CHOP and more Pembrolizumab
  • Circulating tumor DNA analysis was performed during treatment
  • EOW overall response rate (ORR) was 90%, with 62% achieving complete response (CR) at the end of induction
  • 44% of patients achieved ctDNA negativity after 2 cycles of therapy
  • There were no fatal adverse events; however, pneumonitis was noted in 1 patient

Cite This Study

Giri et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d41ahttps://doi.org/10.1182/blood-2025-1016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025
  2. 2R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation2022 · 6 citations
  3. 3Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.2024 · 5 citations
  4. 4Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer2024
  5. 5Final results from the embolden trial:  pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma2025 · 1 citations